{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:18:59Z","timestamp":1788481139656,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["PLBIO2018-160 PIT-MM"],"award-info":[{"award-number":["PLBIO2018-160 PIT-MM"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["PLASMADIFF-3D"],"award-info":[{"award-number":["PLASMADIFF-3D"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["TIE-Skip; 2017-CE15-0024-01"],"award-info":[{"award-number":["TIE-Skip; 2017-CE15-0024-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SIRIC Montpellier Cancer","award":["INCa_Inserm_DGOS_12553"],"award-info":[{"award-number":["INCa_Inserm_DGOS_12553"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01GM122749"],"award-info":[{"award-number":["R01GM122749"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018874","name":"Labex Epigenmed","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018874","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Nationale Contre le Cancer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004795","name":"Institut Universitaire de France","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004795","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fondation Fran\u00e7aise pour la Recherche contre le My\u00e9lome et les Gammapathies monoclonales"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is a malignancy of plasma cells that largely remains incurable. The search for new therapeutic targets is therefore essential. In addition to a wide panel of genetic mutations, epigenetic alterations also appear as important players in the development of this cancer, thereby offering the possibility to reveal novel approaches and targets for effective therapeutic intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Here, we show that a higher expression of the lysine methyltransferase SETD8, which is responsible for the mono-methylation of histone H4 at lysine 20, is an adverse prognosis factor\u00a0associated with a poor outcome in two cohorts of newly diagnosed patients. Primary malignant plasma cells are particularly addicted to the activity of this epigenetic enzyme. Indeed, the inhibition of SETD8 by the chemical compound UNC-0379 and the subsequent decrease in histone H4 methylation at lysine 20 are highly toxic in MM cells compared to normal cells from the bone marrow microenvironment. At the molecular level, RNA sequencing and functional studies revealed that SETD8 inhibition induces a\u00a0mature non-proliferating plasma cell signature and, as observed in other cancers, triggers an activation of\u00a0the tumor suppressor p53, which together cause an impairment of myeloma cell proliferation and survival. However, a deadly level of replicative stress was also observed in p53-deficient myeloma cells treated with UNC-0379, indicating that the cytotoxicity associated with SETD8 inhibition is not necessarily dependent on p53 activation. Consistent with this, UNC-0379 triggers a  p53-independent nucleolar stress characterized by nucleolin delocalization and reduction of nucleolar RNA synthesis. Finally, we showed that SETD8 inhibition is strongly synergistic with melphalan and may overcome resistance to this alkylating agent widely used in MM treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Altogether, our data indicate that the up-regulation of the epigenetic enzyme SETD8 is associated with a poor outcome and the deregulation of major signaling pathways in MM. Moreover, we provide evidences that myeloma cells are dependent on SETD8 activity and its pharmacological inhibition synergizes with melphalan, which could be beneficial to improve MM treatment in high-risk patients whatever their status for p53.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13148-021-01160-z","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T08:02:53Z","timestamp":1631779373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma"],"prefix":"10.1186","volume":"13","author":[{"given":"Laurie","family":"Herviou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ovejero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Izard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ouissem","family":"Karmous-Gadacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Gourzones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Bellanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"De Smedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"De Bruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Grimaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Julien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5717-3207","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Moreaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"1160_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046\u201360.","journal-title":"N Engl J Med"},{"key":"1160_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"93","key":"1160_CR3","first-page":"981","volume":"2018","author":"Multiple myeloma,","year":"2018","unstructured":"Multiple myeloma, . update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;2018(93):981\u20131114.","journal-title":"Am J Hematol"},{"key":"1160_CR4","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3389\/fonc.2018.00566","volume":"8","author":"E De Smedt","year":"2018","unstructured":"De Smedt E, Lui H, Maes K, De Veirman K, Menu E, Vanderkerken K, et al. The epigenome in multiple myeloma: impact on tumor cell plasticity and drug response. Front Oncol. 2018;8:566.","journal-title":"Front Oncol"},{"key":"1160_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13148-018-0554-4","volume":"10","author":"L Herviou","year":"2018","unstructured":"Herviou L, Kassambara A, Boireau S, Robert N, Requirand G, M\u00fcller-Tidow C, et al. PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs. Clin Epigenetics. 2018;10:121.","journal-title":"Clin Epigenetics"},{"key":"1160_CR6","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/s41416-018-0025-x","volume":"118","author":"A Bruyer","year":"2018","unstructured":"Bruyer A, Maes K, Herviou L, Kassambara A, Seckinger A, Cartron G, et al. DNMTi\/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells. Br J Cancer. 2018;118:1062\u201373.","journal-title":"Br J Cancer"},{"key":"1160_CR7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2217\/fon-2016-0329","volume":"13","author":"D Sivaraj","year":"2017","unstructured":"Sivaraj D, Green MM, Gasparetto C. Panobinostat for the management of multiple myeloma. Future Oncol Lond Engl. 2017;13:477\u201388.","journal-title":"Future Oncol Lond Engl"},{"key":"1160_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1101\/gad.177444.111","volume":"26","author":"DB Beck","year":"2012","unstructured":"Beck DB, Oda H, Shen SS, Reinberg D. PR-Set7 and H4K20me1: at the crossroads of genome integrity, cell cycle, chromosome condensation, and transcription. Genes Dev. 2012;26:325\u201337.","journal-title":"Genes Dev"},{"key":"1160_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.tcb.2011.04.006","volume":"21","author":"J Brustel","year":"2011","unstructured":"Brustel J, Tardat M, Kirsh O, Grimaud C, Julien E. Coupling mitosis to DNA replication: the emerging role of the histone H4-lysine 20 methyltransferase PR-Set7. Trends Cell Biol. 2011;21:452\u201360.","journal-title":"Trends Cell Biol"},{"key":"1160_CR10","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1093\/nar\/gkt012","volume":"41","author":"S J\u00f8rgensen","year":"2013","unstructured":"J\u00f8rgensen S, Schotta G, S\u00f8rensen CS. Histone H4 lysine 20 methylation: key player in epigenetic regulation of genomic integrity. Nucleic Acids Res. 2013;41:2797\u2013806.","journal-title":"Nucleic Acids Res"},{"key":"1160_CR11","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1158\/0008-5472.CAN-11-3701","volume":"72","author":"M Takawa","year":"2012","unstructured":"Takawa M, Cho H-S, Hayami S, Toyokawa G, Kogure M, Yamane Y, et al. Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression. Cancer Res. 2012;72:3217\u201327.","journal-title":"Cancer Res"},{"key":"1160_CR12","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.molcel.2007.07.012","volume":"27","author":"X Shi","year":"2007","unstructured":"Shi X, Kachirskaia I, Yamaguchi H, West LE, Wen H, Wang EW, et al. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell. 2007;27:636\u201346.","journal-title":"Mol Cell"},{"key":"1160_CR13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.molcel.2013.04.028","volume":"50","author":"GK Dhami","year":"2013","unstructured":"Dhami GK, Liu H, Galka M, Voss C, Wei R, Muranko K, et al. Dynamic methylation of Numb by Set8 regulates its binding to p53 and apoptosis. Mol Cell. 2013;50:565\u201376.","journal-title":"Mol Cell"},{"key":"1160_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2016.12.038","volume":"390","author":"R Huang","year":"2017","unstructured":"Huang R, Yu Y, Zong X, Li X, Ma L, Zheng Q. Monomethyltransferase SETD8 regulates breast cancer metabolism via stabilizing hypoxia-inducible factor 1\u03b1. Cancer Lett. 2017;390:1\u201310.","journal-title":"Cancer Lett"},{"key":"1160_CR15","doi-asserted-by":"crossref","unstructured":"Veo B, Danis E, Pierce A, Sola I, Wang D, Foreman NK, et al. Combined functional genomic and chemical screens identify SETD8 as a therapeutic target in MYC-driven medulloblastoma. JCI Insight. 2019;4.","DOI":"10.1172\/jci.insight.122933"},{"key":"1160_CR16","first-page":"2185","volume":"39","author":"T Liao","year":"2018","unstructured":"Liao T, Wang Y-J, Hu J-Q, Wang Y, Han L-T, Ma B, et al. Histone methyltransferase KMT5A gene modulates oncogenesis and lipid metabolism of papillary thyroid cancer in vitro. Oncol Rep. 2018;39:2185\u201392.","journal-title":"Oncol Rep"},{"key":"1160_CR17","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3892\/mmr.2015.4733","volume":"13","author":"L Hou","year":"2016","unstructured":"Hou L, Li Q, Yu Y, Li M, Zhang D. SET8 induces epithelial-mesenchymal transition and enhances prostate cancer cell metastasis by cooperating with ZEB1. Mol Med Rep. 2016;13:1681\u20138.","journal-title":"Mol Med Rep"},{"key":"1160_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ccell.2016.12.002","volume":"31","author":"V Veschi","year":"2017","unstructured":"Veschi V, Liu Z, Voss TC, Ozbun L, Gryder B, Yan C, et al. Epigenetic siRNA and chemical screens identify SETD8 inhibition as a therapeutic strategy for p53 activation in high-risk neuroblastoma. Cancer Cell. 2017;31:50\u201363.","journal-title":"Cancer Cell"},{"key":"1160_CR19","doi-asserted-by":"publisher","first-page":"717919","DOI":"10.1155\/2014\/717919","volume":"2014","author":"PJ Teoh","year":"2014","unstructured":"Teoh PJ, Chng WJ. p53 abnormalities and potential therapeutic targeting in multiple myeloma. BioMed Res Int. 2014;2014:717919.","journal-title":"BioMed Res Int"},{"key":"1160_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1182\/blood-2008-10-184226","volume":"114","author":"D Hose","year":"2009","unstructured":"Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A, et al. Induction of angiogenesis by normal and malignant plasma cells. Blood. 2009;114:128\u201343.","journal-title":"Blood"},{"key":"1160_CR21","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1182\/blood-2008-09-178350","volume":"113","author":"D Hose","year":"2009","unstructured":"Hose D, R\u00e8me T, Meissner T, Moreaux J, Seckinger A, Lewis J, et al. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood. 2009;113:4331\u201340.","journal-title":"Blood"},{"key":"1160_CR22","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","volume":"109","author":"G Mulligan","year":"2007","unstructured":"Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007;109:3177\u201388.","journal-title":"Blood"},{"key":"1160_CR23","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1182\/blood-2005-10-4084","volume":"107","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2006;107:2633\u20138.","journal-title":"Blood"},{"key":"1160_CR24","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/leu.2008.99","volume":"22","author":"M Pineda-Roman","year":"2008","unstructured":"Pineda-Roman M, Zangari M, van Rhee F, Anaissie E, Szymonifka J, Hoering A, et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia. 2008;22:1419\u201327.","journal-title":"Leukemia"},{"key":"1160_CR25","first-page":"3096","volume":"60","author":"K Asosingh","year":"2000","unstructured":"Asosingh K, G\u00fcnthert U, Bakkus MH, De Raeve H, Goes E, Van Riet I, et al. In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells. Cancer Res. 2000;60:3096\u2013104.","journal-title":"Cancer Res"},{"key":"1160_CR26","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1158\/1078-0432.CCR-07-4489","volume":"14","author":"E De Bruyne","year":"2008","unstructured":"De Bruyne E, Bos TJ, Asosingh K, Vande Broek I, Menu E, Van Valckenborgh E, et al. Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:2918\u201326.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1160_CR27","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/bjc.2013.392","volume":"109","author":"J Moreaux","year":"2013","unstructured":"Moreaux J, Reme T, Leonard W, Veyrune J-L, Requirand G, Goldschmidt H, et al. Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. Br J Cancer. 2013;109:676\u201385.","journal-title":"Br J Cancer"},{"key":"1160_CR28","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3324\/haematol.2010.033456","volume":"96","author":"J Moreaux","year":"2011","unstructured":"Moreaux J, Klein B, Bataille R, Descamps G, Ma\u00efga S, Hose D, et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica. 2011;96:574\u201382.","journal-title":"Haematologica"},{"key":"1160_CR29","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3324\/haematol.2018.208306","volume":"105","author":"H de Boussac","year":"2020","unstructured":"de Boussac H, Bruyer A, Jourdan M, Maes A, Robert N, Gourzones C, et al. Kinome expression profiling to target new therapeutic avenues in multiple myeloma. Haematologica. 2020;105:784\u201395.","journal-title":"Haematologica"},{"key":"1160_CR30","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1038\/leu.2017.54","volume":"31","author":"E Viziteu","year":"2017","unstructured":"Viziteu E, Klein B, Basbous J, Lin Y-L, Hirtz C, Gourzones C, et al. RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma. Leukemia. 2017;31:2104\u201313.","journal-title":"Leukemia"},{"key":"1160_CR31","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1083\/jcb.200706179","volume":"179","author":"M Tardat","year":"2007","unstructured":"Tardat M, Murr R, Herceg Z, Sardet C, Julien E. PR-Set7-dependent lysine methylation ensures genome replication and stability through S phase. J Cell Biol. 2007;179:1413\u201326.","journal-title":"J Cell Biol"},{"key":"1160_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinforma Oxf Engl. 2013;29:15\u201321.","journal-title":"Bioinforma Oxf Engl"},{"key":"1160_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gb-2004-5-10-r80","volume":"5","author":"RC Gentleman","year":"2004","unstructured":"Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:1.","journal-title":"Genome Biol"},{"key":"1160_CR34","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"1160_CR35","doi-asserted-by":"crossref","unstructured":"Liberzon A, Subramanian A, Pinchback R, Thorvaldsd\u00f3ttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinforma Oxf Engl. 2011;27:1739\u201340.","DOI":"10.1093\/bioinformatics\/btr260"},{"key":"1160_CR36","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci"},{"key":"1160_CR37","doi-asserted-by":"publisher","first-page":"1004077","DOI":"10.1371\/journal.pcbi.1004077","volume":"11","author":"A Kassambara","year":"2015","unstructured":"Kassambara A, R\u00e8me T, Jourdan M, Fest T, Hose D, Tarte K, et al. GenomicScape: an easy-to-use web tool for gene expression data analysis. Application to investigate the molecular events in the differentiation of B cells into plasma cells. PLoS Comput Biol. 2015;11:1004077.","journal-title":"PLoS Comput Biol"},{"key":"1160_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nbt.3051","volume":"33","author":"R K\u00fcffner","year":"2015","unstructured":"K\u00fcffner R, Zach N, Norel R, Hawe J, Schoenfeld D, Wang L, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol. 2015;33:51\u20137.","journal-title":"Nat Biotechnol"},{"key":"1160_CR39","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1038\/s41375-019-0392-1","volume":"33","author":"L Herviou","year":"2019","unstructured":"Herviou L, Jourdan M, Martinez A-M, Cavalli G, Moreaux J. EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation. Leukemia. 2019;33:2047\u201360.","journal-title":"Leukemia"},{"key":"1160_CR40","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.4049\/jimmunol.1101230","volume":"187","author":"M Jourdan","year":"2011","unstructured":"Jourdan M, Caraux A, Caron G, Robert N, Fiol G, Reme T, et al. Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J Immunol. 2011;187:3931\u201341.","journal-title":"J Immunol"},{"key":"1160_CR41","doi-asserted-by":"publisher","first-page":"540","DOI":"10.7150\/thno.28374","volume":"9","author":"V Vikova","year":"2019","unstructured":"Vikova V, Jourdan M, Robert N, Requirand G, Boireau S, Bruyer A, et al. Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance. Theranostics. 2019;9:540\u201353.","journal-title":"Theranostics"},{"key":"1160_CR42","doi-asserted-by":"publisher","first-page":"6822","DOI":"10.1021\/jm500871s","volume":"57","author":"A Ma","year":"2014","unstructured":"Ma A, Yu W, Li F, Bleich RM, Herold JM, Butler KV, et al. Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8. J Med Chem. 2014;57:6822\u201333.","journal-title":"J Med Chem"},{"key":"1160_CR43","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1083\/jcb.200706150","volume":"179","author":"S J\u00f8rgensen","year":"2007","unstructured":"J\u00f8rgensen S, Elvers I, Trelle MB, Menzel T, Eskildsen M, Jensen ON, et al. The histone methyltransferase SET8 is required for S-phase progression. J Cell Biol. 2007;179:1337\u201345.","journal-title":"J Cell Biol"},{"key":"1160_CR44","doi-asserted-by":"publisher","first-page":"402","DOI":"10.4161\/nucl.32235","volume":"5","author":"A James","year":"2014","unstructured":"James A, Wang Y, Raje H, Rosby R, DiMario P. Nucleolar stress with and without p53. Nucleus. 2014;5:402\u201326.","journal-title":"Nucleus"},{"key":"1160_CR45","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1016\/j.celrep.2017.02.021","volume":"18","author":"H Tanaka","year":"2017","unstructured":"Tanaka H, Takebayashi S, Sakamoto A, Igata T, Nakatsu Y, Saitoh N, et al. The SETD8\/PR-Set7 methyltransferase functions as a barrier to prevent senescence-associated metabolic remodeling. Cell Rep. 2017;18:2148\u201361.","journal-title":"Cell Rep"},{"key":"1160_CR46","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/abbs\/gmt011","volume":"45","author":"Y Qin","year":"2013","unstructured":"Qin Y, Ouyang H, Liu J, Xie Y. Proteome identification of proteins interacting with histone methyltransferase SET8. Acta Biochim Biophys Sin. 2013;45:303\u20138.","journal-title":"Acta Biochim Biophys Sin"},{"key":"1160_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lfs.2017.07.025","volume":"186","author":"W Jia","year":"2017","unstructured":"Jia W, Yao Z, Zhao J, Guan Q, Gao L. New perspectives of physiological and pathological functions of nucleolin (NCL). Life Sci. 2017;186:1\u201310.","journal-title":"Life Sci"},{"key":"1160_CR48","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/emboj.2011.364","volume":"31","author":"F Yang","year":"2012","unstructured":"Yang F, Sun L, Li Q, Han X, Lei L, Zhang H, et al. SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities. EMBO J. 2012;31:110\u201323.","journal-title":"EMBO J"},{"key":"1160_CR49","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/emboj.2011.421","volume":"31","author":"I Driskell","year":"2012","unstructured":"Driskell I, Oda H, Blanco S, Nascimento E, Humphreys P, Frye M. The histone methyltransferase Setd8 acts in concert with c-Myc and is required to maintain skin. EMBO J. 2012;31:616\u201329.","journal-title":"EMBO J"},{"key":"1160_CR50","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41375-018-0036-x","volume":"32","author":"KK Jovanovi\u0107","year":"2018","unstructured":"Jovanovi\u0107 KK, Roche-Lestienne C, Ghobrial IM, Facon T, Quesnel B, Manier S. Targeting MYC in multiple myeloma. Leukemia. 2018;32:1295\u2013306.","journal-title":"Leukemia"},{"key":"1160_CR51","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1038\/onc.2011.512","volume":"31","author":"M Bj\u00f6rkman","year":"2012","unstructured":"Bj\u00f6rkman M, \u00d6stling P, H\u00e4rm\u00e4 V, Virtanen J, Mpindi J-P, Rantala J, et al. Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion. Oncogene. 2012;31:3444\u201356.","journal-title":"Oncogene"},{"key":"1160_CR52","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.bbrc.2018.01.049","volume":"496","author":"Y Fu","year":"2018","unstructured":"Fu Y, Yang Y, Wang X, Yin X, Zhou M, Wang S, et al. The histone demethylase PHF8 promotes adult acute lymphoblastic leukemia through interaction with the MEK\/ERK signaling pathway. Biochem Biophys Res Commun. 2018;496:981\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"1160_CR53","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nature09272","volume":"466","author":"W Liu","year":"2010","unstructured":"Liu W, Tanasa B, Tyurina OV, Zhou TY, Gassmann R, Liu WT, et al. PHF8 mediates histone H4 lysine 20 demethylation events involved in cell cycle progression. Nature. 2010;466:508\u201312.","journal-title":"Nature"},{"key":"1160_CR54","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1073\/pnas.93.10.4827","volume":"93","author":"LC Huang","year":"1996","unstructured":"Huang LC, Clarkin KC, Wahl GM. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc Natl Acad Sci U S A. 1996;93:4827\u201332.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1160_CR55","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/1741-7007-11-114","volume":"11","author":"A Loewer","year":"2013","unstructured":"Loewer A, Karanam K, Mock C, Lahav G. The p53 response in single cells is linearly correlated to the number of DNA breaks without a distinct threshold. BMC Biol. 2013;11:114.","journal-title":"BMC Biol"},{"key":"1160_CR56","doi-asserted-by":"publisher","first-page":"4696","DOI":"10.1182\/blood-2010-10-300970","volume":"117","author":"NC Munshi","year":"2011","unstructured":"Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the international myeloma workshop consensus panel 2. Blood. 2011;117:4696\u2013700.","journal-title":"Blood"},{"key":"1160_CR57","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","volume":"28","author":"H Avet-Loiseau","year":"2010","unstructured":"Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:4630\u20134.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1160_CR58","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/leu.2010.175","volume":"24","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M, et al. Treatment of patients with relapsed\/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia. 2010;24:1769\u201378.","journal-title":"Leukemia"},{"key":"1160_CR59","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1182\/blood.V92.3.802","volume":"92","author":"J Drach","year":"1998","unstructured":"Drach J, Ackermann J, Fritz E, Kr\u00f6mer E, Schuster R, Gisslinger H, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92:802\u20139.","journal-title":"Blood"},{"key":"1160_CR60","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/leu.2008.88","volume":"22","author":"G Schilling","year":"2008","unstructured":"Schilling G, Hansen T, Shimoni A, Zabelina T, P\u00e9rez-Sim\u00f3n J-A, Simon-Perez J-A, et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia. 2008;22:1250\u20135.","journal-title":"Leukemia"},{"key":"1160_CR61","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","volume":"128","author":"N Weinhold","year":"2016","unstructured":"Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016;128:1735\u201344.","journal-title":"Blood"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-021-01160-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-021-01160-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-021-01160-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T09:05:48Z","timestamp":1631783148000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-021-01160-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1160"],"URL":"https:\/\/doi.org\/10.1186\/s13148-021-01160-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/776930","asserted-by":"object"}]},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"assertion":[{"value":"12 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"174"}}